

TIRZEPATIDE injection (Mounjaro[®] ▼) for type 2 diabetes

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of TIRZEPATIDE injection (Mounjaro[®] ▼) for type 2 diabetes .

GREY

Tirzepatide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

- > as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
- > in addition to other medicinal products for the treatment of diabetes.^[1]

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of type 2 diabetes should continue to follow national guidance, local pathways, and local formulary choices:

- > NICE Guideline NG28: [Type 2 diabetes in adults: management](#), updated: 29 June 2022.
- > Pan Mersey APC Formulary: [Chapter 6: Endocrine system](#)

References

1. Eli Lilly and Company Limited. Summary of Product Characteristics; [Mounjaro 2.5mg solution for injection in pre-filled pen](#), 26 September 2022. Accessed online 23 November 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.